Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tinzaparin · Innohep

Small molecule · Inhibitor of coagulation factor Xa (F10) and thrombin (coagulation factor IIa) (F2) · developed by Leo Pharma As

Approved FDA, Jul 2000
1 Registered trials

What is Tinzaparin?

Tinzaparin is a low molecular weight heparin obtained by enzymatic depolymerization of porcine intestinal heparin. It acts mainly through antithrombin to inhibit coagulation factors Xa and IIa (thrombin), and it is studied in deep venous thrombosis and pulmonary embolism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Innohep
Drug type
Small molecule
Targets
antithrombin (SERPINC1) (binding partner it blocks), coagulation factor Xa (F10), thrombin (coagulation factor IIa) (F2)
Mechanism
Inhibitor of coagulation factor Xa (F10) and thrombin (coagulation factor IIa) (F2)
Pathways
coagulation cascade, angiogenesis
Therapy area
Cardiovascular
Developer
Leo Pharma As
In trials of
ASPE
FDA status
Approved as Innohep (July 14, 2000), NDA020484 · FDA label
UNII
7UQ7X4Y489

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 24, 2017). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01828697 Phase 4 Deep Venous Thrombosis Completed ASPE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Deep Venous ThrombosisPulmonary Embolism

Other drugs acting on F10 / F2

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.